SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC reports net loss of Rs 17.90 crore for Q3

02 Feb 2012 Evaluate

Sun Pharma Advanced Research Company (SPARC) has suffered a net loss of Rs 17.90 crore in the quarter ended December 31, 2011. The company had reported a net loss of Rs 2.94 crore for the third quarter last fiscal.

Total income of the company stood at Rs 4.51 crore in the quarter ended December 31, 2011. It was Rs 12.17 crore in the corresponding period last fiscal, down by 62.94%.

SPARC was demerged from Sun Pharma as a pharma research and drug discovery company in 2007.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×